Published in Boll Ist Sieroter Milan on July 31, 1978
Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood (1984) 3.65
Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S A (1994) 3.61
Editorial: Measurement of delayed skin-test responses. N Engl J Med (1975) 2.99
Isolation of DNA markers in the direction of the Huntington disease gene from the G8 locus. Am J Hum Genet (1988) 2.11
Whole-blood culture technique for functional studies of lymphocyte reactivity to mitogens, antigens, and homologous lymphocytes. J Lab Clin Med (1973) 1.75
Lymphocyte response to phytohemagglutinin in Hodgkin's disease. Am J Med (1970) 1.56
Antagonism between the effects of insulin and glucagon on the isolated liver. Diabetes (1969) 1.34
New domains of neural cell-adhesion molecule L1 implicated in X-linked hydrocephalus and MASA syndrome. Am J Hum Genet (1995) 1.25
In vitro lymphocyte response to autologous cultured lymphoid cells. Proc Soc Exp Biol Med (1971) 1.20
Complications of BCG vaccination in neoplastic disease. Ann Intern Med (1975) 1.16
Use of Bacillus Calmette-Guérin as adjuvant in human cell vaccines. Cancer Res (1972) 1.15
A simplified technique for in vitro studies of lymphocyte reactivity. Proc Soc Exp Biol Med (1972) 1.12
"Antigenic" disparity between cultured lymphoid cells and autologous lymphocytes. Am J Med (1972) 1.11
Immunotherapy in well-controlled chronic myelocytic leukemia. N Y State J Med (1973) 1.10
Segregation analysis of a marker localised Xp21.2-Xp21.3 in Duchenne and Becker muscular dystrophy families. Hum Genet (1985) 1.09
Salmonellosis in disseminated malignant diseases. A seven-- year review (1959-1965). N Engl J Med (1967) 1.05
Glucagon--an essential hormone. Am J Med (1966) 1.05
Effect of glucagon on gluconeogenesis by the isolated perfused rat liver. Endocrinology (1966) 1.01
Philadelphia-chromosome-positive and -negative chronic myelocytic leukemia. Ann Intern Med (1970) 1.01
Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med (1974) 0.97
Second neoplasms with chronic lymphocytic leukemia. N Y State J Med (1976) 0.97
Pyrogen in the urine of febrile patients with Hodgkin's disease. Nature (1967) 0.93
Effect of BCG on delayed hypersensitivity responses of patients with neoplastic disease. Int J Cancer (1973) 0.91
Basal plasma glucagon levels of man. J Clin Invest (1967) 0.90
Immunologic and biologic properties of antibodies to a glucagon-serum albumin polymer. Endocrinology (1970) 0.90
Longitudinal study of cognitive abilities and adaptive behavior levels in fragile X males: a prospective multicenter analysis. Am J Med Genet (1996) 0.89
Cellular immune responses and prognosis in malignant lymphomas. Natl Cancer Inst Monogr (1971) 0.89
Response to BCG vaccination and survival in advanced Hodgkin's disease. Cancer (1969) 0.89
Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood (1985) 0.89
Myeloid leukemia in Hodgkin's disease: chromosomal abnormalities. Ann Intern Med (1969) 0.87
Longitudinal changes in cognitive and adaptive behavior in fragile X females: a prospective multicenter analysis. Am J Med Genet (1999) 0.86
Human leukemia-associated antigens: detection on cells of established lymphoblastoid lines. J Immunol (1975) 0.86
Molecular cytogenetic evidence for amplification of chromosome-specific alphoid sequences at enlarged C-bands on chromosome 6. Am J Hum Genet (1988) 0.85
Comparison of glucagon and epinephrine effects in the dog. Endocrinology (1966) 0.85
Effect of glucagon on phosphorylase activity of the isolated perfused liver. Am J Physiol (1969) 0.85
Correlation of delayed hypersensitivity responses with chemotherapeutic results in advanced Hodgkin's disease. Cancer (1975) 0.84
Long survival in Hodgkin's disease. Am J Med (1970) 0.84
Bioassay of glucagon using the isolated perfused rat liver. Endocrinology (1970) 0.84
Immunotherapy of chronic myelocytic leukemia. Natl Cancer Inst Monogr (1973) 0.83
Immunologic studies in lymphoma and leukemia, and exploration of antitumor immunotherapy. J Surg Oncol (1973) 0.82
Complete remission in chronic lymphocytic leukemia and leukolymphosarcoma. Cancer (1967) 0.82
Evaluation of survival data for chronic myelocytic leukemia. Am J Hematol (1976) 0.81
Sulfapyridine-induced serum-sickness-like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gamma-globulinopathy. N Engl J Med (1969) 0.80
Suppressive therapy of nontoxic goiter. Am J Med (1974) 0.80
Inhibition of human ovarian carcinoma cell- and hexosaminidase- mediated degradation of extracellular matrix by sugar analogs. Anticancer Res (1992) 0.80
Splenectomy for palliation of chronic myelocytic leukemia. Am J Med (1976) 0.79
Chronic granulocytic leukemia in a patient with sickle cell anemia. Am J Med (1988) 0.79
The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia. J Clin Oncol (1986) 0.78
Immunologic deficiency in Hodgkin's disease. Tumori (1974) 0.78
Prognosis in chronic myeloid leukaemia: biology of the disease vs. treatment. Baillieres Clin Haematol (1987) 0.78
Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules. Ann N Y Acad Sci (1976) 0.77
Moderate versus intensive chemotherapy of prognostically favorable non-Hodgkin's lymphoma: a progress report. Cancer (1980) 0.77
In vitro leukocyte thymidine uptake in chronic lymphocytic leukemia. Cancer Res (1974) 0.77
Failure of diazoxide to affect carbohydrate metabolism of the isolated liver. Diabetes (1968) 0.77
Prognostic features at diagnosis of chronic myelocytic leukemia. Cancer (1981) 0.77
Removal of abnormal clone of leukaemic cells by splenectomy. Br Med J (1975) 0.77
Increased subcellular hyaluronidase in the rat after hydrocortisone injection. Can J Biochem (1971) 0.76
Lack of association between mutation size and cognitive/behavior deficits in fragile X males: a brief report. Am J Med Genet (1996) 0.76
Relationship of serum total IgE and cell-mediated immunity in patients with Hodgkin's disease. Int Arch Allergy Appl Immunol (1977) 0.76
Effect of high spinal cord section on epinephrine hyperglycemia. Am J Physiol (1968) 0.76
The colony-forming cell in the normal and leukemia human host: responses to streptovaricin and rifamycin SV. J Natl Cancer Inst (1974) 0.76
Decreased stainable marrow iron in chronic granulocytic leukemia. Am J Med (1986) 0.75
Survival in Ph1-positive chronic myelocytic leukemia: relationship to findings at diagnosis and to disease kinetics after the first course of treatment. Leuk Res (1985) 0.75
Circulating colony-forming cells in different stages of chronic myelocytic leukemia. Cancer Res (1979) 0.75
Hepatic glycogenolysis induced by glucagon in a patient with type I liver glycogen disease. Biochem Med (1970) 0.75
Is fragile X syndrome a pervasive developmental disability? Cognitive ability and adaptive behavior in males with the full mutation. Am J Med Genet (1994) 0.75
[Warning signs of malignant hemopathies]. Rev Med Liege (1982) 0.75
Leukocyte (3H) thymidine uptake in short-term whole-blood cultures of human and canine renal allograft recipients. J Surg Res (1973) 0.75
Spontaneous remission of leukemic lymphoproliferative disease. Cancer (1971) 0.75
Rater reliability of fragile X mutation size estimates: a multilaboratory analysis. Am J Med Genet (1996) 0.75
In vitro leukocyte thymidine uptake and prognosis in chronic lymphocytic leukemia. Am J Med (1979) 0.75
Immunotherapy for chronic granulocytic leukaemia. Clin Haematol (1977) 0.75
Use of anticancer drugs during pregnancy. Clin Obstet Gynecol (1968) 0.75
In vitro thymidine uptake by circulating leukocytes. J Lab Clin Med (1974) 0.75
Current concepts in the treatment of chronic myelocytic leukemia. Annu Rev Med (1973) 0.75
Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia. Cancer (1987) 0.75
Familial gynecomastia without hypogonadism. South Med J (1979) 0.75
The serological detection of leukemia-associated antigens in chronic leukemia: correlation with disease status. Am J Hematol (1977) 0.75
Thymidine uptake by circulating leukocytes in chronic myelocytic leukemia before and after therapeutic splenectomy. Leuk Res (1980) 0.75
Immunotherapy with cultured human cells and BCG. Transplant Proc (1975) 0.75
Minimum qualifications for directors: DNA-based genetic-testing laboratories. DNA Testing Subcommittee, Quality Assurance Committee, Council of Regional Networks for Genetic Services. Am J Hum Genet (1992) 0.75
Prognostic value of serial measurements of leukocyte thymidine uptake in well-controlled chronic myelocytic leukemia. Leuk Res (1981) 0.75
Significance of Ph1-negative marrow cells in Ph1-positive chronic granulocytic leukemia. Blood (1980) 0.75
Low dose ara-C administered by continuous subcutaneous infusion: a pharmacologic evaluation. Cancer Drug Deliv (1986) 0.75
Thymic irradiation and chronic myelogenous leukemia. N Y State J Med (1977) 0.75
[Isolated superior ophthalmic vein thrombosis due to tamoxifen]. Rev Med Liege (2015) 0.75
[Evaluation of 196 patients with chronic myeloid leukemia based on a standard prognosis model]. Onkologie (1990) 0.75
Use of vinblastine in the terminal phase of chronic myelocytic leukemia. Cancer Treat Rep (1979) 0.75
Effect of glucagon on plasma free fatty acids of normal and pancreatectomized dogs. Am J Physiol (1966) 0.75
Interobserver agreement for measurement of grating acuity and interocular acuity differences with the teller acuity card procedure. Vision Res (1995) 0.75